Globus Medical (GMED) Tops Q1 EPS by 5c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Globus Medical (GMED) PT Raised to $58 at Needham & Company
May 3, 2018 6:38 AM EDTNeedham & Company raised its price target on Globus Medical (NYSE: GMED) to $58.00 (from $57.00) while maintaining a Buy rating.
Analyst Mike Matson commented, "GMED's 1Q18 revenue and EPS beat consensus and management raised its 2018 revenue and EPS guidance. The guidance increases were... More
